Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KQ8W
|
|||
| Drug Name |
SurVaxM
|
|||
| Indication | Glioblastoma of brain [ICD-11: 2A00.00; ICD-10: C71] | Phase 2 | [1] | |
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1 | [2], [3] | ||
| Company |
MimiVax Rochester, NY
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Apoptosis inhibitor survivin (BIRC5) | Target Info | Inhibitor | [4] |
| KEGG Pathway | Hippo signaling pathway | |||
| Hepatitis B | ||||
| Pathways in cancer | ||||
| Colorectal cancer | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Angiogenesis | |||
| Pathway Interaction Database | Aurora B signaling | |||
| Validated targets of C-MYC transcriptional activation | ||||
| FOXM1 transcription factor network | ||||
| Aurora A signaling | ||||
| Reactome | Separation of Sister Chromatids | |||
| Resolution of Sister Chromatid Cohesion | ||||
| RHO GTPases Activate Formins | ||||
| Mitotic Prometaphase | ||||
| WikiPathways | IL-4 Signaling Pathway | |||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
| Mitotic Metaphase and Anaphase | ||||
| Mitotic Prometaphase | ||||
| Apoptosis | ||||
| Interleukin-11 Signaling Pathway | ||||
| Apoptosis Modulation and Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04013672) Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.